Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of candidemia and disseminated candidiasis (including hepatosplenic candidiasis and fungal peritonitis),Treatment of oropharyngeal and esophageal candidiasis,Treatment of vulvovaginal candidiasis (acute and recurrent),Treatment of cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients undergoing chemotherapy or radiation therapy,Off-label: Treatment of coccidioidomycosis, histoplasmosis, blastomycosis, and tinea infections (e.g., tinea pedis, corporis, cruris),Off-label: Prophylaxis of fungal infections in patients with prolonged neutropenia or HIV/AIDS
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. Prolonged in renal impairment (up to 98 hours in creatinine clearance <20 m L/min).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Primarily hepatic metabolism via cytochrome P450 isoenzymes (CYP2C9, CYP3A4, and to a lesser extent CYP2C19). Fluconazole is a moderate inhibitor of CYP2C9 and CYP3A4 and a weak inhibitor of CYP2C19. Approximately 80% of an administered dose is excreted unchanged in urine; the remainder is excreted as metabolites.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal excretion of unchanged drug (~80% of dose). Approximately 11% excreted as metabolites. Biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Plasma protein binding is 11-12%, primarily to albumin. The low binding results in extensive free drug distribution.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Volume of distribution (Vd) is approximately 0.7 L/kg (range 0.5-0.9 L/kg), indicating extensive distribution into total body water and tissues, including penetration into cerebrospinal fluid (CSF), vitreous humor, and peritoneal fluid.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral bioavailability is >90%, essentially complete. Absorption is unaffected by gastric p H or food. Intravenous bioavailability is 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 21-50 m L/min: administer 50% of usual dose; Cr Cl 11-20 m L/min: administer 25% of usual dose; intermittent hemodialysis: administer full dose after each dialysis session
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class A and B: no adjustment; Child-Pugh Class C: insufficient data, use with caution
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Neonates (0-14 days): 6-12 mg/kg IV every 72 hours; Infants/Children (15 days-1 year): 6-12 mg/kg IV every 24 hours; Children >1 year: 6-12 mg/kg IV every 24 hours; maximum 400 mg/day
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustment recommended; monitor renal function and adjust dose based on creatinine clearance due to age-related renal impairment
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Hepatotoxicity: Elevations in liver enzymes have been observed; rare cases of severe hepatic necrosis and fatal hepatic failure have occurred. Discontinue if signs of hepatic injury develop.,QT prolongation: Fluconazole may prolong the QT interval, potentially leading to torsade de pointes. Caution in patients with electrolyte disturbances, bradyarrhythmias, or concurrent use of other QT-prolonging drugs.,Adrenal insufficiency: Cases of reversible adrenal insufficiency have been reported, particularly in patients receiving corticosteroids or those with stress.,Dermatologic reactions: Exfoliative skin disorders (e.g., Stevens-Johnson syndrome) may occur. Discontinue if rash progresses.,Renal impairment: Dose adjustment required in patients with renal dysfunction (Cr Cl <50 m L/min) due to extensive renal elimination.,Pregnancy: Use only if benefit outweighs risk; single-dose therapy for vulvovaginal candidiasis is not recommended during pregnancy.,Lactation: Fluconazole is excreted in human milk; caution in nursing mothers.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to fluconazole or any azole antifungal,Concurrent use of terfenadine (when used at multiple doses of fluconazole ≥400 mg/day) due to risk of serious cardiac arrhythmias,Concurrent use of cisapride due to increased risk of QT prolongation and torsade de pointes,Concurrent use of quinidine, pimozide, or ergot alkaloids (e.g., ergotamine) due to potential for serious adverse effects
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. Avoid alcohol due to potential hepatotoxicity.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous abortion and congenital anomalies (e.g., craniosynostosis, cardiac defects, cleft lip/palate) with prolonged high-dose therapy (≥400 mg/day). Second and third trimesters: low risk at single 150 mg dose; high-dose prolonged use may cause fetal toxicity. Category D for first trimester; Category C for later trimesters.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Fluconazole is excreted into human breast milk with an estimated infant dose of 0.9–3.7% of maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.9–1.0. Single 150 mg dose is considered compatible with breastfeeding. Avoid high-dose prolonged therapy during lactation due to potential infant accumulation and adverse effects (e.g., hepatic toxicity).
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No specific dose adjustment is required for single 150 mg dose for vaginal candidiasis. For systemic infections, use standard dosing (200–400 mg/day) but monitor maternal toxicity and fetal effects. Consider alternative therapy in first trimester. Due to increased volume of distribution and renal clearance in pregnancy, higher doses may be required for life-threatening infections; however, benefit-risk must be evaluated.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Do not use with other fluconazole formulations to avoid dose errors. Monitor renal function and adjust dose in creatinine clearance <50 m L/min. Infuse over 1-2 hours; avoid rapid infusion due to risk of QT prolongation. Check for drug interactions with warfarin, sulfonylureas, phenytoin, and CYP2C9 substrates.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is used to treat fungal infections and is given intravenously.,Report any signs of liver problems (dark urine, yellowing eyes/skin, abdominal pain) or irregular heartbeat immediately.,Avoid alcohol consumption during treatment and for several days after completion.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment early even if you feel better; complete the full course.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% is: 400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.